Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026
Cellectis held its annual shareholders meeting on June 25, 2026, where shareholders approved 29 out of 30 resolutions as recommended by the board. The company continues to advance its pioneering gene-editing platform focused on allogeneic CAR T immunotherapies and gene therapies with end-to-end manufacturing capabilities. The meeting results reinfo…